{
    "nctId": "NCT04486495",
    "briefTitle": "Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer",
    "officialTitle": "Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer (MINIMAX): a Dutch Multicenter Observational Study to Gain Insight in Less and More Invasive Axillary Staging and Treatment in Relation to Oncologic Safety and Quality of Life to Develop Evidence-based Guidelines.",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Neoadjuvant Therapy, Lymph Node Metastases",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 549,
    "primaryOutcomeMeasure": "Disease free survival (DFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female patient with unilateral invasive breast cancer and cN1-3\n* Pathologically proven positive axillary lymph node\n* Planned to undergo neoadjuvant chemotherapy (\u00b1 immunotherapy), followed by staging and treatment of the breast and axilla\n\nExclusion Criteria:\n\n* Clinically node negative breast cancer before NST\n* Bilateral invasive breast cancer\n* Neoadjuvant endocrine therapy\n* Distant metastases (including oligometastatic disease)\n* History of invasive breast cancer\n* Other malignancies, except for basal/squamous cell skin cancer, and in situ carcinoma of the cervix or breast\n* Axillary surgery or radiotherapy before NST (this includes SLNB prior to NST)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}